MZ Diagnostics was founded to develop, validate, and commercialize novel diagnostic applications for implementation on mass spectrometry platforms that address critical clinical needs to improve patient care. The firms introductory effort has focused on the rapid detection of β-lactamase activity, responsible for conferring resistance to penicillin-class antibiotics, for use in hospital-based clinical microbiology laboratories.
